Inhibition of neointimal hyperplasia in a rabbit vein graft model following non-viral transfection with human iNOS cDNA

Gene Therapy

Volumn 20, Issue 10, 2013, Pages 979-986

  Meng, Q H ^a   Irvine, S ^a   Tagalakis, A D ^a   McAnulty, R J ^b   McEwan, J R ^b   Hart, S L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

adventitial; nanoparticles; neointimal hyperplasia

Indexed keywords

BETA GALACTOSIDASE; COMPLEMENTARY DNA; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOFECTIN; NANOPARTICLE; PLASMID DNA; RECEPTOR TARGETED NANOCOMPLEX; UNCLASSIFIED DRUG;

ADVENTITIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSFECTION; GRAFT FAILURE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MORPHOMETRICS; NEOINTIMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PLASMID; PRIORITY JOURNAL; RABBIT; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAPHENOUS VEIN GRAFT; THICKNESS; TREATMENT OUTCOME; TUNICA MEDIA; VEIN GRAFT DISEASE;

ORYCTOLAGUS CUNICULUS;

ANIMALS; CAROTID ARTERIES; DNA, COMPLEMENTARY; GENETIC THERAPY; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; JUGULAR VEINS; MALE; MODELS, ANIMAL; NEOINTIMA; NITRIC OXIDE SYNTHASE TYPE II; RABBITS; TRANSFECTION;

EID: 84885649066     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.20     Document Type: Article

References (44)

1. Scarborough P, Bhatnagar P, Wickramisinghe K, Smolina K, Mitchell C, Rayner M. Coronary Heart Disease Statistics (Oxford, UK, 2010).
2. Izzat MB, West RR, Bryan AJ, Angelini GD. Coronary artery bypass surgery: current practice in the United Kingdom. Br Heart J 1994; 71: 382-385.
3. Kolh P, Wijns W, Danchin N, Di Mario C, Falk V, Folliguet T et al. Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2010; 38(Suppl): S1-S52.
4. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. New Engl J Med 2009; 360: 961-972.
5. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 1998; 97: 916-931.
6. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990; 15: 1667-1687.
7. Campeau L, Hunninghake DB, Knatterud GL, White CW, Domanski M, Forman SA et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. Circulation 1999; 99: 3241-3247.
8. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther 2007; 15: 1233-1247.
9. Mann MJ. Gene therapy for vein grafts. Curr Cardiol Rep 2000; 2: 29-33.
10. Mannion JD, Ormont ML, Shi Y, O'Brien JEJ, Chung W, Roque F et al. Saphenous vein graft protection: effects of c-myc antisense. J Thorac Cardiovasc Surg 1998; 115: 152-161.
11. Mannion JD, Ormont ML, Magno MG, O'Brien JE, Shi Y, Zalewski A. Sustained reduction of neointima with c-myc antisense oligonucleotides in saphenous vein grafts. Ann Thorac Surg 1998; 66: 1948-1952.
12. Shi Y, O'Brien JEJ, Mannion JD, Morrison RC, Chung W, Fard A et al. Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. Circulation 1997; 95: 2684-2693.
13. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354: 1493-1498.
14. Kritz AB, Yu J, Wright PL, Wan S, George SJ, Halliday C et al. In vivo modulation of Nogo-B attenuates neointima formation. Mol Ther 2008; 16: 1798-1804.
15. Eichstaedt HC, Liu Q, Chen Z, Bobustuc GC, Terry T, Willerson JT et al. Gene transfer of COX-1 improves lumen size and blood flow in carotid bypass grafts. J Surg Res 2010; 161: 162-167.
16. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani R, Sukhova G et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1995; 96: 2955-2965.
17. Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000; 355: 213-222.
18. Laitinen M, Pakkanen T, Donetti E, Baetta R, Luoma J, Lehtolainen P et al. Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum Gene Ther 1997; 8: 1645-1650.
19. Irvine SA, Meng QH, Afzal F, Ho J, Wong JB, Hailes HC et al. Receptor-targeted nanocomplexes optimized for gene transfer to primary vascular cells and explant cultures of rabbit aorta. Mol Ther 2008; 16: 508-515.
20. Barbato JE, Tzeng E. iNOS gene transfer for graft disease. Trends Cardiovasc Med 2004; 14: 267-272.
21. Osawa M, Hanada K-I, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstiitution by a single CD34-low/negative hematopoietic stem cell. Science 1996; 273: 242-245.
22. Hu Y, Zhang Z, Torsney E, Afzal AR, Davison F, Metzler B et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoEdeficient mice. J Clin Invest 2004; 113: 1258-1265.
23. Wan S, George SJ, Berry C, Baker AH. Vein graft failure: current clinical practice and potential for gene therapeutics. Gene Therapy 2012; 19: 630-636.
24. Strauss BH, Chisholm RJ, Keeley FW, Gotlieb AI, Logan RA, Armstrong PW. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res 1994; 75: 650-658.
25. Meng QH, Jamal W, Hart SL, McEwan JR. Application to vascular adventitia of a nonviral vector for TIMP-1 gene therapy to prevent intimal hyperplasia. Hum Gene Ther 2006; 17: 717-727.
26. Kibbe MR, Tzeng E, Gleixner SL, Watkins SC, Kovesdi I, Lizonova A et al. Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg 2001; 34: 156-165.
27. McCarthy HO, Coulter JA, Robson T, Hirst DG. Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. J Pharm Pharmacol 2008; 60: 999-1017.
28. Muhs A, Heublein B, Schletter J, Herrmann A, Rudiger M, Sturm M et al. Preclinical evaluation of inducible nitric oxide synthase lipoplex gene therapy for inhibition of stent-induced vascular neointimal lesion formation. Hum Gene Ther 2003; 14: 375-383.
29. Leyen, von der HE, Mugge A, Hanefeld C, Hamm CW, Rau M, Rupprecht HJ et al. A prospective, single-blind, multicenter, dose escalation study of intracoronary iNOS lipoplex (CAR-MP583) gene therapy for the prevention of restenosis in patients with de novo or restenotic coronary artery lesion (REGENT I extension). Hum Gene Ther 2011; 22: 951-958.
30. George SJ, Wan S, Hu J, MacDonald R, Johnson JL, Baker AH. Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation 2011; 124: S135-S142.
31. Channon KM, Qian HS, Youngblood SA, Olmez E, Shetty GA, Neplioueva V et al. Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries: impact on transgene expression and endothelial function. Circ Res 1998; 82: 1253-1262.
32. Channon KM, Qian H, Neplioueva V, Blazing MA, Olmez E, Shetty GA et al. In vivo gene transfer of nitric oxide synthase enhances vasomotor function in carotid arteries from normal and cholesterol-Fed rabbits. Circulation 1998; 98: 1905-1911.
33. Bowey K, Tanguay JF, Tabrizian M. Liposome technology for cardiovascular disease treatment and diagnosis. Expert Opin Drug Deliv 2012; 9: 249-265.
34. Turunen MP, Hiltunen MO, Ruponen M, Virkamaki L, Szoka FCJ, Urtti A et al. Efficient adventitial gene delivery to rabbit carotid artery with cationic polymerplasmid complexes. Gene Therapy 1999; 6: 6-11.
35. Akowuah EF, Gray C, Lawrie A, Sheridan PJ, Su C-H, Bettinger T et al. Ultrasoundmediated delivery of TIMP-3 plasmid DNA into saphenous vein leads to increased lumen size in a porcine interposition graft model. Am J Physiol Heart Circ Physiol 2005; 12: 1154-1157.
36. Yamaoka T, Yonemitsu Y, Komori K, Baba H, Matsumoto T, Onohara T et al. Ex vivo electroporation as a potent new strategy for nonviral gene transfer into autologous vein grafts. Am J Physiol Heart Circ Physiol 2005; 289: H1865-H1872.
37. West NE, Qian H, Guzik TJ, Black E, Cai S, George SE et al. Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: effects on vascular smooth muscle cell differentiation and superoxide production. Circulation 2001; 104: 1526-1532.
38. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-760.
39. Majesky MW, Dong XR, Hoglund V, Mahoney WM, Daum G. The adventitia: a dynamic interface containing resident progenitor cells. Arterio Throm Vasc Biol 2011; 31: 1530-1539.
40. Torsney E, Xu Q. Resident vascular progenitor cells. J Mol Cell Cardiol 2011; 50: 304-311.
41. Mayr U, Zou Y, Zhang Z, Dietrich H, Hu Y, Xu Q. Accelerated arteriosclerosis of vein grafts in inducible NO synthase(-/-) mice is related to decreased endothelial progenitor cell repair. Circ Res 2006; 98: 412-420.
42. Jiang Z, Wu L, Miller BL, Goldman DR, Fernandez CM, Abouhamze ZS et al. A novel vein graft model: adaptation to differential flow environments. Am J Physiol Heart Circ Physiol 2004; 286: H240-H245.
43. Bradbury P, Gordon K. Connective tissues and stains. In: Bancroft JD, Stevens A (eds). Theory and Practice of Histological Techniques. Churchill Livingstone: London, 1992; 119-142.
44. Cunningham S, Meng QH, Klein N, McAnulty RJ, Hart SL. Evaluation of a porcine model for pulmonary gene transfer using a novel synthetic vector. J Gene Med 2002; 4: 438-446.